Reports Q4 revenue $6.41B, consensus $6.09B. Rainer Blair, president and CEO, stated, “We delivered better-than-expected revenue in each of our segments in the fourth quarter-led by respiratory revenue at Cepheid. The combination of higher-than-expected revenues and our team’s strong execution enabled us to exceed our margin and cash flow expectations in what remains a dynamic market environment. Additionally, the recently closed acquisition of Abcam enhances our portfolio and expands our capabilities in the highly attractive proteomics market.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DHR:
- Danaher Reports Fourth Quarter and Full Year 2023 Results
- Early notable gainers among liquid option names on January 26th
- Danaher call volume above normal and directionally bullish
- Netflix upgraded, Tesla initiated: Wall Street’s top analyst calls
- Danaher downgraded to Equal Weight on valuation at Barclays
